Providers

A decade’s worth of data included more than 5 million social determinants of health (SDOH) attributes across nearly 2 million clinical notes from the patient visits extrapolated from a natural language processing system.

To mark the nation's 52nd Earth Day, Robert Feder, MD, outlines how climate change will exacerbate mental health challenges and the importance of global efforts to address the crisis.

Patients with reduced DNA mismatch repair protein expression were more likely to respond to immune checkpoint inhibitors (ICIs), although this study had a small sample size.

A combination of biology, access issues, and delayed diagnoses have contributed to disparities experienced by Black women with metastatic breast cancer, explained Hatem Soliman, MD, medical director of the Clinical Trials Office, Moffitt Cancer Center.

Interviewing both patients and providers, researchers found that while having effective treatments for hidradenitis suppurativa (HS) took precedence across the board, some priorities varied among the 2 groups.

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

This investigation focused on use of additional services and incidence of new diagnoses among women who underwent a breast cancer screening MRI—having a low or average risk of the cancer—compared with a matched cohort who underwent mammography.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.

Key opinion leaders addressed cost, accessibility, and other barriers limiting use of comprehensive genomic profiling (CGP), and how employers can help drive preventive care and precision medicine through CGP.

The lack of effective long-term control of eosinophilic esophagitis (EoE) highlights the unmet need for targeted systemic therapies.

The frequency of global crises such as hurricanes, war, and the pandemic makes a standing committee necessary.

Patients who received early immunosuppressive therapy for their rheumatoid arthritis (RA)–associated peripheral ulcerative keratitis experienced earlier inflammatory control, fewer recurrences, and better visual outcomes.

Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades.

Expression of the chemokine receptor was linked with better overall survival.

Patients may have unrealistic expectations of how a new treatment or procedure may help them, and the conversation between the patient and physician is crucial for setting expectations, explained Robert G. Fante, MD, FACS, president of the American Society of Ophthalmic Plastic & Reconstructive Surgery and facial plastic surgeon and cosmetic surgeon, Fante Eye & Face Centre in Denver, Colorado.

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.

Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.

Predictive models can help find high-risk patients with asthma and manage them proactively, but prior models miss the highest-risk patients and may mislabel low-risk patients.

Alymsys from Amneal Pharmaceuticals and mAbxience is the third biosimilar referencing Avastin approved in the United States and the second of 3 biosimilar approvals Amneal expects in 2022.

This new literature review explored the potential to enhance management for type 1 diabetes (T1D) through the adoption of physiological parameters measured by wearable and sensor-enabled health-related technology.

Delayed diagnosis of wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) results in inappropriate treatments prior to diagnosis and worse clinical outcomes after diagnosis.

News on 2 new CAR T-cell therapies and updates on PARP inhibitors, BTK inhibitors, and biosimilars.

Coverage from the Community Oncology Alliance 2022 Community Oncology Conference, held March 17-18 in Kissimmee, Florida.

Accenture’s 2021 report, “The Future Is Now: How to Drive Precision Oncology Adoption," adds to the chorus calling for greater sharing of data and improved standardization, so that academic centers and community practices alike can continually improve data sets used worldwide.

Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.

Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.

Using data from the National HIV Surveillance System, the National Center for Health Statistics, and the US Census, a team from the CDC investigated lifetime HIV risk in the United States.

It is not yet clear what impact proactive screening might have on health care costs and survival outcomes.